Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
Sandhu, S.K., Omlin, A., Hylands, L., Miranda, S., Barber, L.J., Riisnaes, R., Reid, A.H., Attard, G., Chen, L., Kozarewa, I., Gevensleben, H., Campbell, J., Fenwick, K., Assiotis, I., Olmos, D., Yap, T.A., Fong, P., Tunariu, N., Koh, D., Molife, L.R., Kaye, S., Lord, C.J., Ashworth, A., de Bono, J.
Published in Annals of oncology (01.05.2013)
Published in Annals of oncology (01.05.2013)
Get full text
Journal Article
352 Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients
Sandhu, S.K, Wilding, G, Schelman, W.R, Omlin, A, Kreischer, N, Carpenter, C, Iannone, R, Kaye, S, de-Bono, J.S, Wenham, R.M
Published in European journal of cancer (1990) (01.11.2012)
Published in European journal of cancer (1990) (01.11.2012)
Get full text
Journal Article
1842TiP Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)
de Bono, J.S., Sandhu, S.K., Fizazi, K., Sun, J., Ward, A., Antonarakis, E.S.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
Menzies, A.M., Johnson, D.B., Ramanujam, S., Atkinson, V.G., Wong, A.N.M., Park, J.J., McQuade, J.L., Shoushtari, A.N., Tsai, K.K., Eroglu, Z., Klein, O., Hassel, J.C., Sosman, J.A., Guminski, A., Sullivan, R.J., Ribas, A., Carlino, M.S., Davies, M.A., Sandhu, S.K., Long, G.V.
Published in Annals of oncology (01.02.2017)
Published in Annals of oncology (01.02.2017)
Get full text
Journal Article
362 First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers
Wenham, R.M, Sandhu, S.K, Wilding, G, Sun, L, Toniatti, C, Stroh, M, Carpenter, C, de-Bono, J, Baird, R, Schelman, W.R
Published in European journal of cancer supplements (2010)
Published in European journal of cancer supplements (2010)
Get full text
Journal Article
1608P Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Hofman, M.S., Gafita, A., Bressel, M., Alipour, R., Levy, S., Emmett, L., Ravi Kumar, A.S., Hamid, A.A., Buteau, J.P., Kuo, P.H., Chen, D.L., Hope, T.A., Armstrong, A.J., Scher, H.I., Schoder, H., Sandhu, S.K., Morris, M.J.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1618P Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Hamid, A.A., Thomas, H., Martin, A., Soon, Y.Y., Horvath, L.G., Zielinski, R., Thomson, A., Tan, H., Sandhu, S.K., Reaume, M.N., Pook, D.W., Parnis, F., McDermott, R.S., Lawrence, N., Frydenberg, M., Chi, K.N., Stockler, M.R., Davis, I.D., Sweeney, C.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1654P TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)
de Bono, J.S., Helissey, C., Fizazi, K., Maroto Rey, J.P., Roubaud, G., Antonarakis, E.S., Sandhu, S.K., Shore, N.D., Ratta, R., Perez Valderrama, B., Vulsteke, C., Schafer, L., Marr, G., Zhao, E., Ward, A.F., Piulats Rodriguez, J.M.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1095P Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial
Eggermont, A.M.M., Kicinski, M., Blank, C.U., Mandalà, M., Long, G.V., Atkinson, V.G., Dalle, S., Haydon, A.M., Meshcheryakov, A., Khattak, M.A., Carlino, M.S., Sandhu, S.K., Puig Sarda, S., Ascierto, P.A., Lorigan, P., Grebennik, D., Krepler, C., Marreaud, S.I., Suciu, S., Robert, C.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a phase Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE)
Tolmeijer, S.H., Kwan, E.M., Ng, S.W.S., Joshua, A., Emmett, L., Crumbaker, M., Hamid, A.A., Anton, A., Horvath, L.G., Chan, J., Bressel, M., Buteau, J.P., Dhiantravan, N., Ayati, N., Keerthikumar, S., Goode, D., Hicks, R., Hofman, M.S., Wyatt, A.W., Sandhu, S.K.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
258MO Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) as first-line treatment in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study
Saad, M., Chi, K.N., Sandhu, S.K., Attard, G., Ye, D., Li, L., Jung, W., Pang, S-T., Francis, P.S.J., Li, S., Dibaj, S., Zhang, J., Kim, W., Lopez-Gitlitz, A., Wu, D., Singh, A., De Vries, R., Zhang, L., Lee, J.Y.
Published in Annals of oncology (01.11.2023)
Published in Annals of oncology (01.11.2023)
Get full text
Journal Article
LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE
Chi, K.N.N., Castro, E., Attard, G., Smith, M.R., Sandhu, S.K., Efstathiou, E., Roubaud, G., Small, E.J.J., Gomes, A.J.P.D.S., Rathkopf, D., Saad, M., Gurney, H.P., Jung, W., Mason, G.E., Dibaj, S., Wu, D., Diorio, B., Lopez-Gitlitz, A., Kim, W., Olmos, D.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)
Emmett, L., Subramaniam, S., Crumbaker, M., Joshua, A.M., Weickhardt, A.J., Lee, S.T., Ng, S., Francis, R.J., Goh, J.C.H., Pattison, D.A., Tan, H., Kirkwood, I.D., Sandhu, S.K., Nguyen, A., Gedye, C., Rutherford, N., Hofman, M., Martin, A., Stockler, M.R., Davis, I.D.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
Horvath, L.G., Davis, I.D., Martin, A., Zielinski, R., Thomson, A., Tan, T.H., Sandhu, S.K., Reaume, M.N., Pook, D., Parnis, F., North, S., Marx, G.M., McCaffrey, J.A., McDermott, R.S., Lawrence, N., Frydenberg, M., Chowdhury, S., Chi, K.N.N., Stockler, M.R., Sweeney, C.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
Goode, D., Keerthikumar, S., Gupta, S., Joshua, A.M., Emmett, L., Crumbaker, M., Singer, T., Lam, E., Fernandez, L., Jimenez, E., Zhang, D., Lin, Y., Wenstrup, R.J., PASAM, A., Hicks, R., Kong, G., Hamid, A., Sandhu, S.K.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
LBA41 Long-term survival with neoadjuvant therapy in melanoma: Updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
Long, G.V., Blank, C.U., Amaria, R.N., Hieken, T.J., Sandhu, S.K., Barros, M.J., Mitchell, T.C.C., Eroglu, Z., Samoylenko, I.V., Rutkowski, P., Johnson, D., Pires da Silva, I., Perry, K.A., Tawbi, H.A., Block, M.S., Ascierto, P.A., Burton, E., van Akkooi, A.C.J., Scolyer, R.A., Menzies, A.M.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
LBA42 Distant metastasis-free survival of neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable, macroscopic stage III melanoma: The NADINA trial
Lucas, M.W., Menzies, A.M., Lopez-Yurda, M., Scolyer, R.A., van de Wiel, B., Saw, R.P.M., Van Houdt, W., Maher, N., Torres Acosta, A., Boers-Sonderen, M., Hospers, G., Carlino, M.S., de Groot, J.W., Kapiteijn, E., Suijkerbuijk, K., Rutkowski, P., Sandhu, S.K., Van der Veldt, A.A.M., Long, G.V., Blank, C.U.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
158MO Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study
Binti Saad, M., Chi, K.N., Jung, W., Pang, S-T., Attard, G., Sandhu, S.K., Mason, G.E., del Corral, A., Wang, G., Wu, D., Diorio, B., Lopez-Gitlitz, A., Lee, J.Y.
Published in Annals of oncology (01.11.2022)
Published in Annals of oncology (01.11.2022)
Get full text
Journal Article
LBA44 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
Bottomley, A., Kicinski, M., Long, G.V., Mandala, M., Atkinson, V.G., Blank, C.U., Haydon, A.M., Dalle, S., Khattak, A., Carlino, M.S., Meshcheryakov, A., Sandhu, S.K., Sarda, S.S. Puig, Coens, C., Suciu, S., Grebennik, D., Krepler, C., Lorigan, P., Robert, C., Eggermont, A.M.M.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article